Market Cap 471.76M
Revenue (ttm) 0.00
Net Income (ttm) -83.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 148,900
Avg Vol 226,298
Day's Range N/A - N/A
Shares Out 37.44M
Stochastic %K 85%
Beta -0.34
Analysts Strong Sell
Price Target $39.50

Company Profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORK...

Industry: Biotechnology
Sector: Healthcare
Phone: (650) 606-7910
Website: orukatx.com
Address:
855 Oak Grove Avenue, Suite 100, Menlo Park, United States
BigSqueezeComing
BigSqueezeComing Jul. 2 at 1:08 PM
$ORKA pm gapper
0 · Reply
Quantumup
Quantumup May. 22 at 12:17 PM
BTIG🏁 $ORKA Buy-$44 and said "Orukas pipeline has been carefully curated to improve on market-leading therapies in major IL-23- and IL-17-driven diseases." $PTGX $JNJ $ABBV BTIG added, "Consistent with other spin outs of Paragon Therapeutics (Private), Oruka leverages well-validated YTE modifications to focus on well-defined opportunities where optimized PK has high odds of translating to commercially-relevant improvements in adherence/convenience and potentially better efficacy, while not compromising safety. We expect Oruka's anti-IL-23 (ORKA-001) and anti-IL-17 (ORKA-002) mAbs to thrive as monotherapies and also potentially in combination (ORKA-021), as the targets have complimentary features that could support an ideal induction/maintenance efficacy profile. BTIG went on to say:
0 · Reply
WAYWARD_SUN
WAYWARD_SUN May. 20 at 4:30 PM
0 · Reply
WAYWARD_SUN
WAYWARD_SUN May. 15 at 7:32 PM
0 · Reply
Love_To_Learn
Love_To_Learn May. 13 at 10:46 AM
$BNRG hiding the 0.64 off the 8 spread now after the 0.62/064 2 spread why repkicatign my algo code i placed on $ORKA years ago b4 and after takign them 2 22pt then dropping them cut and pasting their 4.15-4.30 old trigger from 4 years ago +
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 25 at 4:59 PM
$ORKA also update pending
0 · Reply
Bug1
Bug1 Apr. 25 at 10:59 AM
$ORKA the proxy is out agm on june 2nd
0 · Reply
Pika_Capital
Pika_Capital Apr. 22 at 6:19 PM
$ARWR $VRDN $ORKA $SYRE so far so good
0 · Reply
Pika_Capital
Pika_Capital Apr. 9 at 5:46 PM
$ORKA +35% intraday reversal. Holy sh*t. I cant believe they brought it down below cash value
0 · Reply
_www_larval_com_
_www_larval_com_ Apr. 9 at 5:37 PM
$ORKA has soared 8% higher to 5% (~525Kv) a moment ago, 04/17 options, follow for more volatility.
0 · Reply
Latest News on ORKA
Oruka Therapeutics Announces $200 Million Private Placement

Sep 12, 2024, 7:05 AM EDT - 10 months ago

Oruka Therapeutics Announces $200 Million Private Placement


Arca Biopharma stock ($ABIO) soars on merger news

Apr 3, 2024, 11:38 AM EDT - 1 year ago

Arca Biopharma stock ($ABIO) soars on merger news


ARCA biopharma Announces 2023 Financial Results

Feb 1, 2024, 4:35 PM EST - 1 year ago

ARCA biopharma Announces 2023 Financial Results


ARCA biopharma Announces Third Quarter 2023 Financial Results

Oct 18, 2023, 4:25 PM EDT - 1 year ago

ARCA biopharma Announces Third Quarter 2023 Financial Results


ARCA biopharma Announces Second Quarter 2023 Financial Results

Jul 21, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Second Quarter 2023 Financial Results


ARCA biopharma Announces First Quarter 2023 Financial Results

Apr 24, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces First Quarter 2023 Financial Results


James Flynn Joins ARCA biopharma Board of Directors

Dec 19, 2022, 4:05 PM EST - 2 years ago

James Flynn Joins ARCA biopharma Board of Directors


ARCA biopharma Announces Third Quarter 2022 Financial Results

Oct 28, 2022, 4:15 PM EDT - 2 years ago

ARCA biopharma Announces Third Quarter 2022 Financial Results


Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

Jun 21, 2022, 4:05 PM EDT - 3 years ago

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors


ARCA biopharma Announces First Quarter 2022 Financial Results

May 2, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces First Quarter 2022 Financial Results


BigSqueezeComing
BigSqueezeComing Jul. 2 at 1:08 PM
$ORKA pm gapper
0 · Reply
Quantumup
Quantumup May. 22 at 12:17 PM
BTIG🏁 $ORKA Buy-$44 and said "Orukas pipeline has been carefully curated to improve on market-leading therapies in major IL-23- and IL-17-driven diseases." $PTGX $JNJ $ABBV BTIG added, "Consistent with other spin outs of Paragon Therapeutics (Private), Oruka leverages well-validated YTE modifications to focus on well-defined opportunities where optimized PK has high odds of translating to commercially-relevant improvements in adherence/convenience and potentially better efficacy, while not compromising safety. We expect Oruka's anti-IL-23 (ORKA-001) and anti-IL-17 (ORKA-002) mAbs to thrive as monotherapies and also potentially in combination (ORKA-021), as the targets have complimentary features that could support an ideal induction/maintenance efficacy profile. BTIG went on to say:
0 · Reply
WAYWARD_SUN
WAYWARD_SUN May. 20 at 4:30 PM
0 · Reply
WAYWARD_SUN
WAYWARD_SUN May. 15 at 7:32 PM
0 · Reply
Love_To_Learn
Love_To_Learn May. 13 at 10:46 AM
$BNRG hiding the 0.64 off the 8 spread now after the 0.62/064 2 spread why repkicatign my algo code i placed on $ORKA years ago b4 and after takign them 2 22pt then dropping them cut and pasting their 4.15-4.30 old trigger from 4 years ago +
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 25 at 4:59 PM
$ORKA also update pending
0 · Reply
Bug1
Bug1 Apr. 25 at 10:59 AM
$ORKA the proxy is out agm on june 2nd
0 · Reply
Pika_Capital
Pika_Capital Apr. 22 at 6:19 PM
$ARWR $VRDN $ORKA $SYRE so far so good
0 · Reply
Pika_Capital
Pika_Capital Apr. 9 at 5:46 PM
$ORKA +35% intraday reversal. Holy sh*t. I cant believe they brought it down below cash value
0 · Reply
_www_larval_com_
_www_larval_com_ Apr. 9 at 5:37 PM
$ORKA has soared 8% higher to 5% (~525Kv) a moment ago, 04/17 options, follow for more volatility.
0 · Reply
Pika_Capital
Pika_Capital Apr. 4 at 7:05 PM
Pika is too old to be shaken out of dev stage bios gamble basket. You sell, I BUY. Added chunks of $ARWR $VRDN $ORKA and $SYRE at these insane levels. Dev stage bios are trading as they are going COMPLETELY OUT OF BUSINESS lol 🤡 I will revisit this post in a year or so
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 1 at 7:03 PM
$ORKA -0.80* for the day 0.8 pocket active on beloved temp support behind the 0.85 take note $AKBA that 10.24 belongs to your chart !
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 1 at 7:01 PM
$ORKA getting access to your movement now indirectly using a vessel in $AAL 10.24 data transfer march 3rd ORKA open 10.16* data transfer 10.24 synching with beloved
0 · Reply
Pika_Capital
Pika_Capital Apr. 1 at 3:31 PM
$ORKA loaded under $10 Massive bear market for dev stage bios. Someone says it's opportunity, someone says everything going to zero. This q1 selling is way overblown. $XBI
0 · Reply
_www_larval_com_
_www_larval_com_ Mar. 31 at 7:53 PM
$PRTG 4%[-6%] $ASPI 4%[9%] $BIYA -3%[-13%] $ORKA -3%[-18%] $MLGO 3%[38%] most notable movement into the final minutes of trading.
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 25 at 11:00 AM
$ORKA will be affected today and will be on this for maintaining order and support ! GLTA
0 · Reply
Pika_Capital
Pika_Capital Mar. 17 at 5:09 PM
$ORKA 40 watchers. I loaded around $11 area for $6-7k. Either worthless or 10x bagger in 5 years. I like my chances
0 · Reply
Quantumup
Quantumup Mar. 8 at 6:35 PM
Stifel reiterated $ORKA Buy-$49 after $ORKA's 4Q24 update—says it thinks ORKA-001 has potential for best-in-class efficacy/dosing in the PsO market and beyond, as it shares the same MOA Skyrizi ( $ABBV)—ORKA-002 (preclinical data at #AAD2025, Mar 7-11) targeting IL-17A/F could ultimately achieve a superior profile vs. Bimzelx ( $UCBJY). Stifel said in its note to investors:
0 · Reply
DonCorleone77
DonCorleone77 Mar. 6 at 9:39 PM
$ORKA Oruka Therapeutics reports Q4 EPS (49c), consensus (98c) "We made tremendous progress in our first year as a company, including our successful public debut, raising over $475 million to fund the company through 2027, and advancing ORKA-001 into the clinic," said Lawrence Klein, CEO of Oruka. "As we move into 2025, we are excited about the momentum ahead, with our first clinical data readout anticipated later this year as well as our plans to advance ORKA-002 into the clinic and ORKA-001 into Phase 2 development. Looking forward, we expect to deliver a clinical catalyst every six months, which could progressively establish ORKA-001 and ORKA-002 as the best treatment options in the incredibly important therapeutic area of psoriatic disease."
0 · Reply
JTonelli
JTonelli Jan. 16 at 6:11 PM
$ORKA This has set like 5 new 52 week lows today on light volume. Not sure why I held shares here for a couple of days and was lucky to escape with just a 3% loss
0 · Reply
JTonelli
JTonelli Jan. 16 at 6:08 PM
$ORKA I am glad I sold for a small loss yesterday. This trades exactly like ABIO used to and that is warning enough to stay away. Its down 7% on extremely low volume which just means there are no buyers. Basically you hold this hoping for a homerun before they have to RS again. There are much better options out there if you want to risk your money on a bio. A seller owned and controlled ticker is not a place for bulls.
0 · Reply
STAresearch
STAresearch Jan. 15 at 5:01 AM
$PACS $CSTM $ORKA AI-Powered 3 "Top Picks" https://www.youtube.com/watch?v=jD4Mw6aZfdE
0 · Reply